This was a prospective, randomized, open-label, blinded end point (PROBE), 30 parallel group study with two treatment arms. A total of 160 outpatients aged 61–75 years entered a 2-week wash-out period ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) ...